×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Session 4: Global Phase 1
Session Chair(s)
Toshihiko Doi, MD, PhD
Deputy Director / Chief, Experimental Therapeutics
National Cancer Center Hospital East, Japan
Noboru Yamamoto, MD, PhD
Deputy Director, Department of Experimental Therapeutics
National Cancer Center Hospital, Japan
Speaker(s)
Global Phase I Studies – Looking from Both Sides – the Academic and CRO Perspectives
Johanna Bendell, MD
Sarah Cannon, United States
Chief Development Officer, Director, Drug Development Unit Nashville
First-in-Human Phase 1 Studies in Oncology: The New Challenge for Asian Investigational Sites
Toshio Shimizu, MD, PhD
National Cancer Center Hospital, Japan
Head of Physician (Oncology Phase 1 Unit), Dept of Experimental Therapeutics
Experiences of Global Phase I Studies - Growth and Challenges -
Satoshi Nishioka, MSc
Daiichi Sankyo Co., Ltd., Japan
Early Clinical Development Department, Group II
Global Phase 1 from the Points of Japan Affiliate of US based Company
Tomoko Takami
MSD K.K., Japan
Director, Oncology Clinical Development, Oncology Science Unit